Malaria remains one of the leading causes of death among children in sub-Saharan Africa, claiming more than 600,000 lives each year worldwide with limited efficacy in currently available treatments and vaccines. Now a new early-stage clinical trial found that a novel monoclonal antibody provided dose-dependent full protection against the malaria parasite with minimal side effects.
from Medical Xpress - latest medical and health news stories https://ift.tt/oyctOgf
